tiprankstipranks
Trending News
More News >
Strides Pharma Science Ltd (IN:STAR)
:STAR
India Market
Advertisement

Strides Pharma Science Ltd (STAR) Price & Analysis

Compare
1 Followers

STAR Stock Chart & Stats


Financials

STAR FAQ

What was Strides Pharma Science Ltd’s price range in the past 12 months?
Strides Pharma Science Ltd lowest stock price was ₹530.70 and its highest was ₹1675.25 in the past 12 months.
    What is Strides Pharma Science Ltd’s market cap?
    Strides Pharma Science Ltd’s market cap is ₹84.58B.
      When is Strides Pharma Science Ltd’s upcoming earnings report date?
      Strides Pharma Science Ltd’s upcoming earnings report date is Jul 30, 2025 which is in 11 days.
        How were Strides Pharma Science Ltd’s earnings last quarter?
        Strides Pharma Science Ltd released its earnings results on May 22, 2025. The company reported ₹8.918 earnings per share for the quarter, beating the consensus estimate of N/A by ₹8.918.
          Is Strides Pharma Science Ltd overvalued?
          According to Wall Street analysts Strides Pharma Science Ltd’s price is currently Overvalued. Get more investment ideas with TipRanks Premium
            Does Strides Pharma Science Ltd pay dividends?
            Strides Pharma Science Ltd pays a Annually dividend of ₹807.849 which represents an annual dividend yield of 0.27%. See more information on Strides Pharma Science Ltd dividends here
              What is Strides Pharma Science Ltd’s EPS estimate?
              Strides Pharma Science Ltd’s EPS estimate for its next earnings report is not yet available.
              How many shares outstanding does Strides Pharma Science Ltd have?
              Strides Pharma Science Ltd has 92,162,710 shares outstanding.
                What happened to Strides Pharma Science Ltd’s price movement after its last earnings report?
                Strides Pharma Science Ltd reported an EPS of ₹8.918 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 5.094%.
                  Which hedge fund is a major shareholder of Strides Pharma Science Ltd?
                  Currently, no hedge funds are holding shares in IN:STAR

                  Company Description

                  Strides Pharma Science Ltd

                  Strides Pharma Science Limited develops, manufactures, and sells pharmaceutical products in Africa, Australia, North America, Europe, Asia, India, and internationally. It operates through two segments, Pharmaceutical and Biopharmaceutical. The company offers pharma generics in various forms, such as tablets, hard and soft gelatin capsules, sachets, and liquids, as well as nasal spray, powders, solids, ointments, and creams. It also develops branded generics products for the treatment of chronic therapies, including women's health, central nervous system, cardiovascular, diabetes, dermatology, and probiotics under the Renerve, Unibrol, Combiart, Duotab, and Vitafer brands; and anti-retroviral, anti-malarial, anti-tuberculosis, Hepatitis, and other infectious disease drug segments for institutional business. The company was formerly known as Strides Shasun Limited and changed its name to Strides Pharma Science Limited in July 2018. Strides Pharma Science Limited was incorporated in 1990 and is headquartered in Bengaluru, India.
                  Similar Stocks
                  Company
                  Price & Change
                  Follow
                  Alkem Laboratories Ltd.
                  Aurobindo Pharma Ltd
                  Glenmark Pharmaceuticals Limited
                  IPCA Laboratories Limited
                  Laurus Labs Ltd.
                  Popular Stocks
                  What am I Missing?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis